References
- Alvarenga L, Moreau V, Felicori L, et al (2010). Design of antibody-reactive peptides from discontinuous parts of scorpion toxins. Vaccine, 28, 970-80. https://doi.org/10.1016/j.vaccine.2009.10.135
- Ansari HR, Raghava GP (2010). Identification of conformational B-cell Epitopes in an antigen from its primary sequence. Immunol Res, 6, 6.
- Arensa R, Hallb TV, van der Burgb SH (2013). Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. Sem Immunol, 25, 182-90. https://doi.org/10.1016/j.smim.2013.04.008
- Awada A, Bozovic-Spasojevic I, Chow L (2012). New therapies in HER2-positive breast cancer: a major step towards a cure of the disease? Cancer Treatment Reviews, 38, 494-504. https://doi.org/10.1016/j.ctrv.2012.01.001
- Axelsena TV, Holma A, Christiansena G, Birkelund S (2011). Identification of the shortest AB-peptide generating highly specific antibodies against the C-terminal end of amyloid-B42. Vaccine, 29, 3260-9. https://doi.org/10.1016/j.vaccine.2011.02.026
- Bian H, Reidhaar-Olson JF, Hammer J (2003). The use of bioinformatics for identifying class II-restricted T-cell epitopes. Meth, 29, 299-309. https://doi.org/10.1016/S1046-2023(02)00352-3
- Calabrich A, Fernandes GS, Katz A (2008). Trastuzumab: mechanisms of resistance and therapeutic opportunities. Oncol, 22, 1250-8.
- Chen P, Rayner S, Hu KH (2011). Advances of bioinformatics tools applied in virus epitopes prediction. Virologica Sinica, 26, 1. https://doi.org/10.1007/s12250-011-3159-4
- Chen SW, Van Regenmortel MH, Pellequer JL (2009). Structure-activity relationships in peptide-antibody complexes: implications for epitope prediction and development of synthetic peptide vaccines. Curr Med Chem, 16, 953. https://doi.org/10.2174/092986709787581914
- Cho HS, Mason K, Ramyar KX, et al (2003). Structure of the extracellular region of HER2 alone and in complex with the herceptin fab. Nature, 421, 756-60. https://doi.org/10.1038/nature01392
- Correa I, Plunkett T (2001). Update on HER-2 as a target for cancer therapy HER2/neu peptides as tumour vaccines for T cell recognition. Breast Cancer Res, 3, 399-403. https://doi.org/10.1186/bcr330
- Dakappagari NK, Douglas DB, Triozzi PL, et al (2000). Prevention of mammary tumors with a chimeric Her-2 B-cell epitope peptide vaccine. Cancer Res, 60, 3782-9.
- Dakappagari NK, Pyles J, Parihar R, et al (2003). Multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol, 170, 4242-53. https://doi.org/10.4049/jimmunol.170.8.4242
- De Groot AS, Cohen T, Ardito M, et al (2010). Use of bioinformatics to predict MHC ligands and T-cell epitopes: application to epitope-driven vaccine design. Methods Microbiol, 37, 35-66. https://doi.org/10.1016/S0580-9517(10)37003-6
- Disis M, Schiffman K (2001). Cancer vaccines targeting the HERZ/neu oncogenic protein. Sem Oncol, 28, 12-20. https://doi.org/10.1053/sonc.2001.28545
- Donnes P, Elofsson A (2002). Prediction of MHC class I binding peptides, using SVMHC. BMC Bioinformatics, 3, 25. https://doi.org/10.1186/1471-2105-3-25
- Doytchinova IA, Flower DR (2002). Quantitative approaches to computational vaccinology. Immunol Cell Biol, 80, 270-9. https://doi.org/10.1046/j.1440-1711.2002.01076.x
- Firat H, Garcia-Pons F, Tourdot S, et al (1999). H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J Immunol, 29, 3112. https://doi.org/10.1002/(SICI)1521-4141(199910)29:10<3112::AID-IMMU3112>3.0.CO;2-Q
- Fisher RD, Ultsch M, Lingel A, et al (2010). Structure of the complex between HER2 and an antibody paratope formed by side chains from tryptophan and serine. J Mol Biol, 402, 217. https://doi.org/10.1016/j.jmb.2010.07.027
- Franklin MC, Carey KD, Vajdos FF, et al (2004). Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell, 5, 317-28. https://doi.org/10.1016/S1535-6108(04)00083-2
- Gangwara RS, Shil P, Sapkala GN, Khanc SA, Gore MM (2012). Induction of virus-specific neutralizing immune response against West Nile and Japanese encephalitis viruses by chimeric peptides representing T-helper and B-cell epitopes. Vir Res, 163, 40-50. https://doi.org/10.1016/j.virusres.2011.08.008
- Garrett JT, Kaumaya P, Pei D, Dalbey R, Magliery T (2007). Peptide based B cell epitope vaccines targeting HER-2/Neu. PhD thesis. Ohio State University, Ohio, USA.
- Goede A, Jaeger IS, Preissner R (2005). SUPERFICIAL-Surface mapping of proteins via structure-based peptide library design. BMC Bioinformatics, 6, 223. https://doi.org/10.1186/1471-2105-6-223
- Gritzapis AD, Fridmanb A, Pereza SA, et al (2010). HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor properties. Vaccine, 28, 162-70.
- Gritzapis AD, Voutsas IF, Lekka E, et al (2008). Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties. J Immunol, 181, 146-54. https://doi.org/10.4049/jimmunol.181.1.146
- Guan P, Doytchinova IA, Zygouri C, Flower DR (2003). MHCPred: a server for quantitative prediction of peptide-MHC binding. Nucleic Acids Res, 31, 3621-4. https://doi.org/10.1093/nar/gkg510
- Haste Andersen P, Nielsen M, Lund O (2006). Prediction of residues in discontinuous B-cell epitopes using protein 3D structures. Protein Sci, 15, 2558-67. https://doi.org/10.1110/ps.062405906
- Jacot W, Fiche M, Zaman K (2013). The HER2 amplicon in breast cancer: topoisomerase IIA and beyond. Biochim Biophys Acta (BBA), 1836, 146-57.
- Kageyama S, Kitano S, Hirayama M, et al (2008). Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel. Cancer Sci, 99, 601. https://doi.org/10.1111/j.1349-7006.2007.00705.x
- Kastenmuller W, Gasteiger G, Gronau JH, et al (2007). Cross-competition of CD8+T cells shapes the immunodominance hierarchy during boost vaccination. J Exp Med, 204, 2187. https://doi.org/10.1084/jem.20070489
- Kennedy R, Celis E (2008). Multiple roles for CD4+ T cells in antitumor immune responses, Immunol Rev, 222, 129. https://doi.org/10.1111/j.1600-065X.2008.00616.x
- Kobayashi H, Celis E (2008). Peptide epitope identification for tumorreactive CD4 T cells. Cur Opin Immunol, 20, 221. https://doi.org/10.1016/j.coi.2008.04.011
- Kobayashi H, Wood M, Song Y, Appella E, Celis E (2000). Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res, 60, 5228-36.
- Kulkarni-Kale U, Bhosle S, Kolaskar AS (2005). CEP: a conformational epitope prediction server. Nucleic Acids Res, 33, 168-71.
- Kumar S, Hinks JA, Maman JC, et al (2011). p185, an immunodominant epitope, is an autoantigen mimotope. J Bio Chem, 286, 26220. https://doi.org/10.1074/jbc.M111.224303
- Lax I (1988). Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling. Mol Cell Biol, 8, 1831-4.
- Lebreton A, Moreau V, Lapalud P, et al (2011). Discontinuous epitopes on the C2 domain of coagulation Factor VIII mapped by computer-designed synthetic peptides. Bri J Haematol, 155, 487-97. https://doi.org/10.1111/j.1365-2141.2011.08878.x
- Li GF, Wang Y, Zhang ZS (2005). Identification of immunodominant Th1-type T cell epitopes from Schistosoma japonicum 28 kDa glutathione-Stransferase, a vaccine candidate. Acta Biochim Biophys Sin, 37, 751-8. https://doi.org/10.1111/j.1745-7270.2005.00111.x
- Mahdavi M, Mohabatkar H, Keyhanfar M, Jafarian Dehkordi A, Rabbani M (2012). Linear and conformational B cell epitope prediction of HER 2 ECD-subdomain III by in silico methods. Asian Pac J Cancer Prev, 13, 3053. https://doi.org/10.7314/APJCP.2012.13.7.3053
- Maupetit J, Derreumaux P, Tuffery P (2009). PEP-FOLD: an online resource for de novo peptide structure prediction. Nucleic Acids Res, 37, 498-503. https://doi.org/10.1093/nar/gkp323
- Miyako H, Kametani Y, Katano I, et al (2011). Antitumor effect of new HER2 peptide vaccination based on B cell epitope. Anticancer Res, 31, 3361-8.
- Moreau V, Fleury C, Piquer D, et al (2008). PEPOP: computational design of immunogenic peptides. BMC Bioinformatics, 9, 71. https://doi.org/10.1186/1471-2105-9-71
- Nair S, Kukreja N, Singh BP, Arora N (2011). Identification of B cell epitopes of alcohol dehydrogenase allergen of Curvularia lunata. PLoS ONE, 6, 20020. https://doi.org/10.1371/journal.pone.0020020
- Noguchi M, Sasada T (2013). Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol Immunother, 62, 919-29. https://doi.org/10.1007/s00262-012-1379-1
- Parker KC, Bednarek MA, Coligan JE (1994). Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol, 152, 163.
- Pellequer JL, Westhof E, Van Regenmortel MH (1994). Epitope prediction from primary structure of proteins. In Peptide Antigens: A Practical Approach. GB Wisdow ed. Oxford, IRL Press.
- Rammensee HG, Bachmann J, Emmerich NN, Bachor OA, Stevanovic S (1999). SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics, 50, 213-9. https://doi.org/10.1007/s002510050595
- Ripoll DR (1992). Conformational study of a peptide epitope shows large preferences for beta-turn conformations. Int J Pept Protein Res, 40, 575-81.
- Roggen EL (2008). B-cell epitope engineering: a matter of recognizing protein features and motives. Drug Discovery Today: Technologies, 5, 49-55. https://doi.org/10.2174/157016308783769478
- Rosenberg S (2001). Progress in human tumor immunology and immunotherapy. Nature, 411, 380-4. https://doi.org/10.1038/35077246
- Senpuku H, Kato H, Takeuchi H, Noda A, Nisizawa T (1997). Identification of core B cell epitope in the synthetic peptide inducing cross inhibiting antibodies to surface protein antigen of streptococcus mutans. Immunol invest, 26, 531-48. https://doi.org/10.3109/08820139709088538
- Singh AK, Rathb SK, Misraa K (2011). Identification of epitopes in Indian human papilloma virus 16 E6: A bioinformatics approach. J Vir Methods, 177, 26-30. https://doi.org/10.1016/j.jviromet.2011.06.006
- Singh H, Raghava GPS (2001). ProPred: Prediction of HLA-DR binding sites. Bioinformatics, 17, 1236-7. https://doi.org/10.1093/bioinformatics/17.12.1236
- Siyi H, Zhiqiang Z, Liangwei L, et al (2008). Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism. Proteins, 70, 938-49.
- Tai W, Mahato R, Cheng K (2010). The role of HER2 in cancer therapy and targeted drug delivery. J Control Rel, 146, 264-75. https://doi.org/10.1016/j.jconrel.2010.04.009
- Thompson JD, Higgins DG, Gibson TJ (1994). CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res, 22, 4673. https://doi.org/10.1093/nar/22.22.4673
- Van Regenmortel MH (1996). Mapping epitope structure and activity: from onedimensional prediction to four-dimensional description of antigenic specificity. Meth, 9, 465. https://doi.org/10.1006/meth.1996.0054
- Vita R, Zarebski L, Greenbaum JA, et al (2010). The immune epitope database 2.0. Nucleic Acids Res, 38, 854-62. https://doi.org/10.1093/nar/gkp1004
- Wallecha A, Ramos K, Malinina I, Singh R (2012). Listeria monocytogenes-based bivalent Lm-LLO immunotherapy for the treatment of HER2/neu positive and triple negative breast cancer and its impact on immunosuppression. Cancer Research, 72, 4-5. https://doi.org/10.1158/1538-7445.AM2012-4
- Wang B, Kaumaya PTP, Cohn DE (2010). Immunization with synthetic VEGF peptides in ovarian cancer. Gyn Oncol, 119, 564-70. https://doi.org/10.1016/j.ygyno.2010.07.037
- Weber CA, Mehta PJ, Ardito M, et al (2009). T cell epitope: friend or foe? Immunogenicity of biologics in context. Adv Drug Delivery Rev, 61, 965-76. https://doi.org/10.1016/j.addr.2009.07.001
- Wiwanitkit V (2007). Predicted epitopes of Lig A of Leptospira interrogans by bioinformatics method: a clue for further vaccine development. Vaccine, 25, 2768-70. https://doi.org/10.1016/j.vaccine.2006.12.023
- Zaks TZ, Rosenberg SA (1998). Immunization with a peptide epitope from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res, 58, 4902-8.
Cited by
- Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines vol.10, pp.7, 2014, https://doi.org/10.1586/1744666X.2014.916211
- Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer vol.35, pp.12, 2014, https://doi.org/10.1007/s13277-014-2503-y
- Production and Characterization of New Anti-HER2 Monoclonal Antibodies vol.34, pp.3, 2015, https://doi.org/10.1089/mab.2014.0092
- In Silico Analysis of Synaptonemal Complex Protein 1 (SYCP1) and Acrosin Binding Protein (ACRBP) Antigens to Design Novel Multiepitope Peptide Cancer Vaccine Against Breast Cancer pp.1573-3904, 2018, https://doi.org/10.1007/s10989-018-9780-z